Fig. 5: The Hippo pathway drives resistance in persister cells in EGFR mutant lung cancer. | Communications Biology

Fig. 5: The Hippo pathway drives resistance in persister cells in EGFR mutant lung cancer.

From: Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer

Fig. 5

a Nuclear/cytoplasmic YAP1/WWTR1 expression ratio by immunofluorescence (normalised to day 1 DMSO) in PC-9, HCC927, and HCC4006 cells following osimertinib treatment over a time course (2, 3, and 7 days; Wilcoxon rank sum test, ***P < 0.001). b mRNA expression of Hippo transcripts CTFG, CYR61, and AMOTL2 at 48 hours post osimertinib treatment. c 5-day viability assay of a concentration range of either K-975 or MYF-01-037 TEAD inhibitors combined with a fixed dose of osimertinib. d 21-day viability assay of osimertinib (160 nM) and K-975 (300 nM) alone versus in combination in PC-9, HCC827, and HCC4006 cells.

Back to article page